Contributing Member of the Healthcare Councils

GLG News by this Author

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Temporary reprieve for Wockhardt in High court

March 24, 2011

Analysis of:High Court stays winding up order against Wockhardt; stock down | economictimes.indiatimes.com

The Bombay High court recently stayed the winding up petition filed by QVT advisors & other FCCB holders until May 4th.This is a temporary reprieve for Wockhardt & should be used to sit across the table & settle the matters with FCCB holders.The company needs to focus its energies on the core business, it has already wasted a lot of time, money & effort on legal & other issues.QVT are not going to leave unless they get paid.

Wochardt winding up petition admitted

March 17, 2011

Analysis of:Court admits winding-up plea against Wockhardt | www.business-standard.com

In a major set back to Wockhardt, Bombay High court recently admitted a winding up petition filled by various FCCB bond holders including QVT advisors.Just when things where looking bright for Wockhardt this comes as a major set back as it will again drag the company into legal tangle rather than focusing on business.It has taken the company nearly 4 years to come of the last mess & this particular one can get really messy.

A USD 40 Billion opportunity Indian pharma is not going to miss

February 9, 2011

Analysis of:Indian cos eye $4bn generic opportunity | timesofindia.indiatimes.com

CEOs of most Indian pharma companies have already set a timer on their desk indicating the time of most sought after drugs coming off patent in US.For the past 3 - 4 years Indian companies have been preparing to launch their Generic counter part for products like Lipitor, Plavix, Actos, Effoxor etc.... The current sale for some of these block busters is around 30 - 40 Billion USD. 

Wockhardt - taking baby steps to recovery

February 9, 2011

Analysis of:Stocks | economictimes.indiatimes.com

The recently declared Wockhardt Q# results have caught every one by surprise. Wockhardt has been struggling for the past 2 - 3 year for survival & has tried its best to get its house in order.The result of all the restructuring, reorganizing, etc... are evident.In the process Wockhardt has lost a lot of flab & is now a very lean company with focus of pharmaceuticals alone.

Over Cook the Turkey - Sell it to the Japanese !!!

October 4, 2010

Analysis of:Taisho leads bids for India's Paras Pharma -report | Reuters | www.reuters.com

Paras Pharmaceuticals, the next Block buster deal about to explode on the Indian PE scene!!!Actis & Sequoia are looking at 30 - 40 X their initial investments.Whom to sell an overcooked turkey!!! - call the Japanese!!!Most Indian companies will not be able to swallow such valuations even though the Brands on offer are leaders in their segments.After Daichii - Ranbaxy deals - there seems to a eagerness in Japan to enter the Emerging markets like India at any cost.

Lupin steadily building its American treasury chest

October 4, 2010

Analysis of:Lupin gets USFDA nod for generic high blood pressure tablets | www.business-standard.com

Lupin Pharmaceuticals a Indian Pharma company through it's subsidiary is already 5th largest pharma company in terms of number of products prescribed.With today news of FDA approval of Hozaar & Cozaar brands, both used for High blood pressure a chronic disease which require daily medication on long term basis.These two product categories have has sales of $ 1.6 billion in last financial year.Lupin is currently one of the most aggressive company of Indian origin in the US pharma space. 

Paras Pharma PE investors about to "Sing all the way to the Bank"!!!!

September 30, 2010

Analysis of:CORRECTED - Five global drug cos approached for Paras stake-report | Reuters | in.reuters.com

Paras Pharma - a private company based in the state of Gujarat, India has a fairly well established presence in OTC & FMCG segments of the market.Its brands like MOOV are best sellers in its category, but even in the wildest imagination no one would have valued the company at USD 1 Billion. Going by the current demand of the PE investors asking price, the company is valued at USD 1 Billion & the PE's stake value close to 700 million USD. This multiple times their original investment. 

Wockhardt - Baby steps towards recovery!!!

September 21, 2010

Analysis of:Myiris news - Live News - Wockhardt in talks over bonds conversion price | www.myiris.com

Wockhardt has been in news recently, but fortunately there is good news coming from the company this time.Wockhardt has agreed to issue convertible bonds to investor (those who were suing it) & get over with it's liabilities.Currently the Bond conversion price is being negotiated & soon we hope all this will be over & Wockhardt will be back in business.

Sun Pharma & Taro pharma battle of Ego's !!!

September 21, 2010

Analysis of:The Telegraph - Calcutta (Kolkata) | Opinion | The sun goes places | www.telegraphindia.com

Sun & Taro have been engaged in a bitter taker over battle for last couple of years.Sun which currently holds close to 35% of Taro cannot do much because at every stage there are hurdles in the form of litigations & appeals.Both the companies have spent considerable amount of time & money on litigation there by hurting the shareholders more than any gain possible from this deal.Taro is trying every trick in the book to avoid been acquired by Sun Pharma, while in its part Sun in doing everything.

Strides one of the rising stars of Indian Pharma industry

August 25, 2010

Analysis of:Strides eyes M&As for speciality pharma, R&D | economictimes.indiatimes.com

Strides is taking huge strides in terms of growth, it is one of the fastest growing company in the Indian space. The path adopted by Strides is organic & inorganic, Strides has been acquiring companies left right & center & forming JVs.Currently it has a good range of regular Generic medicines & has been lacking specialty product offering. Going by the current market trends margins are lucrative in Speciality pharma segment due to less number of players & complicated nature of the products.

Wockhardt - Do we see light????

August 20, 2010

Analysis of:Wockhardt shares surge on settlement hopes | www.business-standard.com

Market is flooded with positive news from Wockhardt recently.Losses trimmed in the last quarter, growth of their business in India, US FDA approvals of some molecules etc....Wockhardt is definitely working towards getting out of the woods.Todays developments are more significant, there is news that Wockhardt is offering to settle with QVT Advisors & other FCCB bond holders.

Lupin Sues Ranbaxy in US!!! - Dog Eat Dog competition is hear to stay!!!

August 10, 2010

Analysis of:Lupin sues Ranbaxy in US for patent infringement | www.business-standard.com

Lupin Sues Ranbaxy in US for Patent Infringement, this is novel !!! Whats at stake - a Multi million dollar Cholesterol lowering drug - Fenofibrate. Cholesterol lowering drugs are one of the fastest growing category in the US & the world.Lupin having paid close to $ 40 million for buy the rights for US is not going to take this lightly.We are going to be witnessing a coming of age battle of Indian pharma sector were two fraternity brothers fight each other for a very lucrative market

Indian Pharma companies report stronger than expected growth for last quarter

July 28, 2010

Results are out for last quarter & Pharma industry in India has reported a very strong quarterly performance. Companies like Glenmark have reported 191 % increase YoY while Strides Arco labs have reported 41% increase.Overall it reflects a strong recovery in Indian & overseas market for the industry.Today majority of Indian pharma companies have close to 50% for their business overseas & hence this performance has more significance as it's an indication of markets overseas.

Is its the end of the road for Wockhardt ?????

June 23, 2010

Analysis of:Wockhardt promoters pledge 61.87% stake | www.business-standard.com

Today leading Indian dailies are carrying news articles that Wockhardt Promoters have pledged their entire holdings in Wockhardt to an un-known party.Wockhardt and its management have been struggling with a huge debt of close to a billion dollars for near 3 years now.There have been rumors for some time that the company was on the block. Today's news is an indication of an indirect / covert sale.Wockhardt's troubles will not end with a simple payment of debt.

Dr. Reddy's looking for its Billion $ deal !!!

June 22, 2010

Analysis of:Dr Reddy's may sell stake in domestic formulations biz | www.business-standard.com

Going buy the current trend of Indian born pharma companies selling out to foreign companies, Dr. Reddy's does not want to be left out.Dr. Reddy's as a strong local presence & is known for its 1st to market strategies.In last decade Dr. Reddy's has built a nice comfortable niche for its self in domestic market.Going by the valuations on offer for Indian companies Dr. Reddy's is expecting any where between 2.5 - 3 billion USD for its Domestic formulation business.

Orchid - Next wave of Indian companies taking lead!!!!

June 11, 2010

Analysis of:Orchid to buy US' Karalex Pharma-Pharmaceuticals-Healthcare/Biotech-News By Industry-News-The Economic Times | economictimes.indiatimes.com

Orchid Chemicals & Pharmaceuticals, one the up coming pharma companies from India is taking the tried & tested path to growth.With big players like Ranbaxy & Piramal acquired, it leaves the ground open for smaller companies like Orchid to take the lead in Generic Pharma business.This is in line to my last article describing that we will see many SMEs taking lead in the coming years.Recent buyout of Karalex Pharmaceuticals US by Orchid may take time to generate results.

Abbott's Multi billion $$$ buy out puts shifts focus on Emerging pharma players

June 9, 2010

Analysis of:Ipca Laboratories outperformers in pharma space: Sharmila Joshi-Views/Recommendations-Stocks-Markets-The Economic Times | economictimes.indiatimes.com

The recent Abbott take over of Indian pharma company Piramal healthcare will result in shift  of focus to emerging medium sized companies.The company we are referring here is IPCA labs. IPCA and other small to medium sized company are now in the lime light.Many big daddies of Indian pharma are currently evaluating offers from Western Multinationals.This leaves the field open for Medium size enterprise to seize market share.IPCA has been largely successful in this we will see many more companies

Is Glenmark next in line after Piramal Healthcare ????

May 29, 2010

Analysis of:Glenmark Pharma expects 11-12 new USFDA nods in FY11 - Reuters - | www.moneycontrol.com

Glenmark has been consistently bring in goods news for the past couple of weeks.After the recent Primal healthcare sale to Abbott, it appears Glenmark is working on its valuations.It is trying to get the best valuation possible in this market & that would be in same range as Piramal 3 - 4 billion USD.If all indications are interpreted correctly we should expect some big news from Glenmark soon!!!

Abbott gets it's Indian Souvenir !!!! Bets big on Emerging Markets

May 24, 2010

Analysis of:Abbott buys Piramal's formulations business | www.in.com

Further to my article dated 19/5/10 it seems every bit was true, Primal Healthcare did sell its business & Abbott did out bid all its competitors.As per the deal Abbott valued Piramal Healthcare at 9x last years sales.Thats a considerably high price to pay, but what did it get in return???There are many things to gain from Abbott's point of view.Abbott so far was considered a Niche player with some expensive products & very few mass market products. 

Big boys of Pharma - looking for their Indian Souvenir - Piramal Healthcare most suited!!!

May 19, 2010

Analysis of:UPDATE 2-India's Piramal denies stake sale reports, shares fall| Reuters | www.reuters.com

Pharma & Healthcare going through a churning in the tradition or regulated markets like the US / Europe.Governments of these countries are behind healthcare players to rationalize cost.Margins are under pressure, growth is stagnant, competition has increased.What do you do in such a situation, look for un - regulated markets where the Cowboy operations can be shifted.India & its fertile markets are currently focus of every sector including Pharma.

Page : 123456Next1 to 20 of 107